Embed Size (px)
Citation preview
Dr Zafar Iqbal
M.Phil., Ph.D., Postdoctorate
My objective is a challenging career for development of state-of-the-art
research, teaching and clinical (Molecular Diagnostics / MDx) program in the fields of
Medical Genetics, Molecular Hematology and Cancer Genomics.
Phone: +966-53-86-355-86, E-mail: [email protected]
Academic Qualifications:
Sr. # Degrees Year Marks Division
1) Post-doctorate (Post-PhD) 2007-2008 (Shanghai Jiao-Tong University (SJTU), China)
(Fellowship in Clinical Hematology / Oncology & Functional Medical Genomics)
2) Ph.D.* (Doctorate) 2001-2007 (SJTU & University of the Punjab, Pakistan)
(Molecular Genetics / Hematology & Oncology)
3) M.Phil. (MS) 1999-2001 755/1100 1ST
(Molecular Biology / Biomedical sciences)
4) M.Sc. (Masters) 1996-1999 748/1200 1ST
(Biological/Basic biomedical sciences)
5) B.Sc. (Bachelor) 1993-1996 438/800 2ND
(Biology / Biomedical sciences)
6) F.SC. (Grade-12) 1991-1993 741/1100 1ST
7) S.S.C. (Grade-10) 1989-1991 709/850 1ST
*PhD work was carried out at SJTU School of Medicine Shanghai China, University of Tokyo Hospital Japan and National Institute for Biotechnology & Genetic Engineering (NIBGE), Faisalabad, Pakistan, and degree was awarded by University of the Punjab Lahore Pakistan.
Page 1 of 32
Clinical / Molecular Diagnostic (MDx) Experience:
1) Founder of Molecular Genetic Pathology Unit and pioneer in introducing molecular
diagnosis of hematological cancers and solid tumors at King Khalid University Hospital,
King Saud University College of Medicine, Riyadh, KSA (07-06-2010 to 14-05-2012).
2) Founder Scientist of Molecular Genetic Testing of Leukemia/Lymphoma and Solid
Tumors at Health Sciences Laboratories, Department of Zoology, University of the
Punjab, Lahore, Pakistan (02-2006 to 12-2006 & 1-2009 to up-to-date) which is
currently Pakistan’s largest centre for research, teaching and molecular diagnostics
in Molecular Hematology, Leukemia/ Lymphoma Genetics and solid tumors.
3) Pioneer in introducing the molecular hematology/oncology tests and quality control
measures of infectious molecular diagnostics at Ammar Medical Complex, Chughtai
Lahore Laboratories Pakistan (12-2009 to 5-2010).
4) Introduced BCR-ABL molecular testing for diagnosis of Chronic Myeloid Leukemia
at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan
(04-2009 to 11-2009).
5) Introduced BCR-ABL mutation testing for Chronic Myeloid Leukemia drug-
resistance monitoring and co-established 8-color flow cytometry for diagnosis of
hematological malignancies at Shanghai Institute of Hematology of Rui-Jin Hospital,
Shanghai Jiao-Tong University School of Medicine China (2007-2008).
6) Developed Molecular Testing of Alpha Thalassemia, BRCA1/2 mutation testing in
Breast/ Ovarian cancers, Acute Leukemia and Familial Hypercholesterolemia
Molecular Testing (LDLR gene) for PIBS Diagnostics at Human Molecular Genetics
Laboratory, National Institute for Biotechnology and Genetic Engineering (NIBGE),
Faisalabad, Pakistan (5-2002 to 1-2006).
7) Introduced Molecular Testing of Acute Leukemia at Department of Pathology and
Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh,
Saudi Arabia (12-2006 to 3-2007).
Page 2 of 32
Employment Record (Research, Teaching and Clinical):
Visiting Scientist and Principal Investigator, “Hematology Oncology and
Pharmacogenetic Engg. Sciences (H.O.P.E.S.)” Program, Health Sciences/Parasitology
Research Group, Dep’t of Zoology, University of the Punjab, Lahore, Pakistan (Since
1/2009).
Visiting Professor of Medical Biotechnology , Next Generation Medical Biotechnology
Division, Department of Biotechnology, University of Sargodha, Pakistan (Since July
2012).
Assistant Professor (Medical Genetics / Hematology & Oncology) , CAMS, King Saud
Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Since November
2012).
Quality Assurance and Academic Accreditation Program Officer (CLSP), CAMS,
King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Since
February 2014).
Assistant Professor and Group Leader Functional Molecular Cell Biology / Clinical
Hematology & Oncology: Centre for Research in Molecular Medicine (CRiMM) /
Institute of Molecular Biology and Biotechnology (IMBB), the University of Lahore,
Lahore, Pakistan (12/ 2009 to 05-06-2012).
Consultant Molecular Diagnostics / Genetics and In-charge PCR Laboratory,
Ammar Medical Complex and Chughtais Lahore Laboratories (CLL), Lahore. Pakistan
(12-2009 to 05-2010).
Jr. Research Scientist and Group Leader Hemato-oncology: Shaukat Khanum
Memorial Cancer Hospital and Research Centre, Lahore, Pakistan (5/2009 to 11/2009).
Page 3 of 32
Senior Research Officer (SRO): Centre for Excellence in Molecular Biology (CEMB),
University of the Punjab Lahore Pakistan (1/2009 to 5/2009).
Post-doctoral Scientist (Functional Medical Genomics / Hematology and Oncology):
State Key Laboratory of Functional Medical Genomics, Shanghai Institute of
Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, China
(7/2007-12/2008).
Post-doctoral Researcher: “Hematology, Oncology and Pharmacogenetics” at
University of the Punjab, Lahore 54590, Pakistan (3/2007 to 7/2007).
Molecular Hematologist: King Faisal Specialist Hospital and Research Hospital
(KFSH&RC) Riyadh Saudi Arabia (12/2006 to 3/2007).
Researcher: “Hematology, Oncology and Pharmacogenetic-Engineering Sciences
(H.O.P.E.S.), Health Sciences/Parasitology Research Group, Department of Zoology,
University of the Punjab, Lahore 54590, Pakistan” (2/2006 to 11/2006).
Research Officer: Department of Physiology and Cell Biology, University of Health
Sciences, Lahore 54600, Pakistan (4/2006 to 9/2006).
Scientific Officer / Junior Scientist: Cancer Genetic/Human Molecular Genetics
Laboratory, at National Institute for Biotechnology & Genetic Engineering (NIBGE),
Faisalabad, Pakistan from (5/2002 to 1/2006).
Research officer: H.O.P.E.S., Dep’t. of Zoology, University of the Punjab, Lahore,
Pakistan (3/2001 to 5/2002).
Research Scholar (Molecular Biomedical sciences): Center of Excellence in Molecular
Biology (CEMB), Punjab University Lahore Pakistan (3/1999-2001). At the completion
of research at CEMB, Degree of Master of Philosophy (MPhil) in Molecular Biology was
awarded.
Page 4 of 32
List of Publications
Full-text Articles:
1. Sabar MF,…, Iqbal Z, et. al. Sequence Variants on 17q21 are Associated with the
Susceptibility of Asthma in the Population of Lahore, Pakistan. J asthma (In Press),
accepted on 23rd Jan 2015.
2. Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M, Sani S, Qazi MH, Kamal
MA, Iqbal Z, Hussain A. Assessment of circulating biochemical markers and
antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid
leukemia (AML) patients. Saudi J Biol Sci. 2015 Jan; 22(1):106-11.
3. Iqbal Z. Molecular genetic studies on 167 pediatric ALL patients from different areas
of Pakistan confirm a low frequency of the favorable prognosis fusion oncogene TEL-
AML1 (t 12; 21) in underdeveloped countries of the region. Asian Pac J Cancer Prev.
2014; 15(8):3541-6.
4. Tayyab M, Khan M, Akhtar T, Iqbal Z, Noor Z, Noor N. Distinct Gene Mutations,
their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid
Leukemia (AML). J Cancer Sci Ther 2014, 6:337-349. doi: 10.4172/1948-
5956.1000292. http://omicsonline.org/open-access/distinct-gene-mutations-their-
prognostic-relevance-and-molecularly-targeted-therapies-in-acute-myeloid-
leukemia-aml-1948-5956.1000292.pdf
Page 5 of 32
5. Iqbal Z, Akhtar T, Akram AM, Khalid M, Shah IH, Aleem A, et al. Detection of
Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel
K245N Mutation Associated with Primary Nilotinib Resistance By Employing a
Newly Developed Cost Effective BCR-ABL Sequencing Protocol. Blood 2014: 124
(21): 1810. http://www.bloodjournal.org/content/124/21/1810.
6. Iqbal Z. A comprehensive analysis of breakpoint cluster region-abelson fusion
oncogene splice variants in chronic myeloid leukemia and their correlation with
disease biology. Indian J Hum Genet. 2014 Jan; 20(1):64-8.
7. Akram A, Akhtar T and Iqbal Z. Survival assessment and Optimization of BCR/ABL-
KD amplification protocol for detection of Imatinib resistant mutations in Ph+
Chronic Myeloid Leukemia patients from Pakistan
Gene therapy & molecular biology 02/2014; 16:10. 0.72 Impact Factor
http://www.gtmb.org/volumes/Vol16/2.Akram_et_al_10-29.pdf
8. Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A. Immunological
evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox. J
Coll Physicians Surg Pak. 2014 Jul;24(7):467-71.
9. Rasool M, Rashid S, Arooj M… Iqbal Z, Gan SH, Kamal MA, Sheikh IA. New
possibilities in hepatocellular carcinoma treatment. Anticancer Res. 2014 Apr;
34(4):1563-71.
10. Rasool M, Malik A, Qazi A, Sheikh I, Manan A, Shaheen S, Iqbal Z et al.
Current View From Alzheimer Disease To Type 2 Diabetes Mellitus. CNS &
Neurological disorders-Drug Targets 2014 Apr; 13(3):533-42.
Page 6 of 32
11. Shahbaz S, Akhtar T, Iqbal Z. Optimization of nested RT-PCR for the detection
of a common fusion oncogene AML1/ETO of Acute Myeloid Leukemia in Pakistan.
Biologia 2014 (In press).
12. Karim S; Ansari SA; Rasool S; Iqbal S; Sohrab SS; Abuzenadah AM and Al-
Qahtani M. Transcriptomics study of neurodegenerative disease: Emphasis on
synaptic dysfunction mechanism in Alzheimer’s disease. CNS & Neurological
disorders-Drug Targets 2014 (In Press).
13. Alanazi A, Alsalmeh M, Alsomali O, Almurshdi AM, Alabdali A, Al-Sulami
M, Al-Nemer A, Al-Qusairy A, Aloraibi S and Iqbal Z. Poor Basic Life Support
Awareness among Medical and College of Applied Medical Sciences Students
Necessitates the Need for Improvement in Standards of BLS Training and Assessment
for Future Health Care Providers. Middle-East Journal of Scientific Research 21 (5):
848-854, 2014. DOI: 10.5829/idosi.mejsr.2014.21.05.82335
http://www.idosi.org/mejsr/mejsr21%285%2914/21.pdf
14. Alanazi A, Al Moamary M, Ismaeli T, Alanazi AN, Olayan LH, Alanazi AM,
Abu Nurah HY, Iqbal Z and Qureshi S. The Reliability of the Arabic Version of the
Asthma Knowledge Questionnaire and Assessment of the Level of Asthma Awareness
among Parents of Children with Asthma in Saudi Arabia. Middle-East Journal of
Scientific Research 20(4):412-418, 2014. DOI: 10.5829/idosi.mejsr.2014.20.04.82258.
http://www.idosi.org/mejsr/mejsr20%284%2914/2.pdf
15. Iqbal Z , Aleem A, Iqbal M,…, Khalid AM et al. Detection of pre-existing
BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic phase
chronic myeloid leukemia patients is associated with imatinib resistance: First large-
scale study with implication in post-Imatinib era. PLoS ONE 2013; 8(2): e55717.
doi:10.1371/journal.pone.0055717.
Page 7 of 32
16. Aleem A, Anjum F, Algahtani F, Iqbal Z, Alsaleh K. Clofarabine in the
treatment of elderly patients with acute myeloid leukemia. Asian Pac J Cancer Prev.
2013; 14(2):1089-92.
17. Awan T, Iqbal Z, Aleem A, Sabir N, Absar M, Rasool M et al, . Five Most
Common Prognostically Important Fusion Oncogenes are Detected in the Majority of
Pakistani Pediatric Acute Lymphoblastic Leukemia Patients and are Strongly
Associated with Disease Biology and Treatment Outcome. Asian Pac J Cancer Prev.
2012; 13(11):5469-5475.
18. Iqbal Z . Molecular Hematology in Leukemia Biology and Treatment: Past,
present and future. J. App. Hematol. 2012 October; 3(2):55-61.
19. Begum M, Karim S, Malik A, Khurshid R, Asif M, Salim A, Nagra SA, Zaheer
A, Iqbal Z, Abuzenadah AM, Alqahtani MH, Rasool M.CA 15-3 (Mucin-1) and
Physiological Characteristics of Breast Cancer from Lahore, Pakistan. Asian Pac J
Cancer Prev. 2012; 13(10):5257-61.
20. Aleem A, Al Diab AR, Alsaleh K, Algahtani F, Alsaeed E, Iqbal Z, El-Sherkawy
MS. Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients.
Asian Pac J Cancer Prev., 2012; 13(4):1311-5.
21. Sabir N, Iqbal Z , Aleem A, Awan T, Naeem T, Asad S, et al. Prognostically
Significant Fusion Oncogenes in Pakistani Patients with Adult Acute Lymphoblastic
Page 8 of 32
Leukemia and Their Association with Disease Biology and Outcome. Asian Pac J
Cancer Prev., 2012;13(7):3349-55..
22. Iqbal Z , Manzoor F, Iqbal M, Ali S, Sheikh N, Khan M; Aleem A , Tanveer A.
Frequency of BCR-ABL Fusion Oncogene Splice Variants Associated with Chronic
Myeloid Leukemia (CML). Journal of Cancer Therapy, 2011, 2, 176-180.
23. Malik S, Hanif A, Khokher S, Iqbal Z, Rana S, Imran M, Bilal M, Arslan M.
Association of genetic and non-genetic risk factors with specific BRCA mutation
positive breast cancers in some Pakistani females. Pak J Physiol 2009;5(1): 51-57.
24. Iqbal Z., Iqbal M. and Akhtar T. Frequency of BCR-ABL fusion oncogene in
Pakistani childhood acute lymphoid leukaemia (ALL) patients reflects ethnic
differences in molecular genetics of ALL.J. Paed. Hemat. Oncol., 2007, 29 (8): 585.
25. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Ahmad M. Khalid. Case study of
primary Imatinib resistance and correlation of BCR-ABL multiple mutations in
chronic myeloid leukemia. Therapy (2004), 1(2): 249-254.
26. Iqbal Z., Siddiqui R.T. and Qureshi J. A. Two different point mutations in BCR-
ABL gene ATP-binding domain conferring primary Imatinib resistance in a chronic
Page 9 of 32
myeloid leukemia (CML) patient: a case report. Biol. Proced. Online 2004; 6(1): 144-
148.
27. Zafar Iqbal , Ijaz Shah, Aamer Aleem, Mubashar Naqvi, Ammara Tahir, et al.
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly
diagnosed chronic phase CML patients and their association with imatinib resistance.
Nature Precedings Online. 28 November 2011.
http://precedings.nature.com/documents/6645/version/1.
28. Iqbal Z., Siddiqui R. T. and Qureshi J. A. Detection of point mutations
conferring acquired and natural Gleevec resistance in chronic myeloid leukemia
patients. J. Pak. Med. Assoc., December 2003, 53(12): 9-10.
29. Tanveer, A., and Iqbal, Z. 2000. Isolation of Bacillus sp., from water samples
collected from snail habitats and its evaluation as biomolluscicide. Punjab Univ. J.
Zool., 15: 171-181.
30. Iqbal Z., Muqaddas A. and Tanveer A. Evaluation of Bacillus sp. as
biomolluscicide against freshwater snail Lymnaea acuminata. Punj. Univ. J. Zool.,
2000, 9: 50-57.
Page 10 of 32
31. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on bacteria isolated from
freshwater physid snail and their evaluation as snail controlling agent. Acta Scientia,
January 1999, 9: 58-68.
32. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on pathogenic bacteria
isolated from freshwater lymnaid snails and their evaluation as snail controlling agent.
Acta Scientia, January 1999, 9: 69-78.
Abstracts published in ISI-indexed journals:
33. Zafar Iqbal, Tashfin Awan, Tanveer Akhtar, Aleem Aamer, Noreen Sabir,
Muhammad Absar, Iqbal Mudassar, Ahmad Mukhtar Khalid, Giuseppe Saglio,
Mahmood Rasool, and Akhtar Hussain. High Frequency Of BCR-ABL/t(22;9)
Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL
Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors
In Pediatric ALL Treatment Protocols. Blood 2013 122:3908.
34. Zafar Iqbal, Saba Shahzadi, Tanveer Akhtar, Aleem Aamer, Ahmad Mukhtar
Khalid, and Iqbal Mudassar. BCR-ABL Splice Variants In Three Phases Of CML:
Association With Disease Biology and Response To Imatinib. Blood 2013 122:5191.
35. Zafar Iqbal , Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad
Sultan, et al. Characterization of Common Fusion Oncogenes As Prognostic
Page 11 of 32
Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need
for Genetic Testing At Presentation, Molecular Prognostication and Differential
Treatment. Blood (ASH Annual Meeting Abstracts) 120 (21): 5115. (Impact Factor
9.90)
36. Zafar Iqbal , Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad
Sultan, et al. Detection of Five Common Fusion Oncogenes in Pakistani Children with
Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and
Treatment Outcome. Blood (ASH Annual Meeting Abstracts) 120 (21): 5124. (Impact
Factor 9.90)
37. Zafar Iqbal , Tashfeen Awan, Mudassar Iqbal, Noreen Sabir. High frequency of
BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as
revealed by RT-PCR and interphase FISH: association with disease biology and
treatment outcome. J Clin Oncol 30, 2012 (suppl): 6612 (Proceedings of 2012 Annual
Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA). (Impact
Factor 18.372)
38. Zafar Iqbal , Mudassar Iqbal, Tanveer Akhtar, Mubashar Iqbal Naqvi, Ammara H
Tahir, Tariq Jameel Gill, et al . Presence of Prior-to-Treatment BCR-ABL Mutations
In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and
Their Correlation with Imatinib Resistance: Implications of Cancer
Page 12 of 32
Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of
BCR-ABL+ Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (21): 2278.
(Impact Factor 9.90)
39. Z Iqbal , N Sabir, M Iqbal, A Tashfeen, A Aleem, A Mukhtar Khalid, T Akhtar.
Poor Outcome Of TCF3-PBX1 Despite Its Association With Favorable Risk Factors
Stresses The Need For Intensified Remission Therapy For Patients Of This Genetic
Subgroup In Adult Acute Lymphoid Leukemia. Haematologica 2013; 98(s1): 264.
EHA Abstract n. P625 (Impact Factor 6.424).
40. Z Iqbal , A Tashfeen, M Iqbal, N Sabir, A Aleem, A Mukhtar Khalid, T Akhtar.
High Frequency of BCR-ABL In Pediatric Acute Lymphoid leukemia with Poor
Outcome Identifies The Immediate Need For Incorporation of Imatinib And Other
Tyrosine Kinase Inhibitors In Treatment Protocols. Haematologica 2013; 98(s1): 268.
EHA Abstract n. P635 (Impact Factor 6.424).
41. Iqbal Z , Li-Juan Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer
A.. First comprehensive study on pre-existing BCR-ABL KD mutations and
subsequent Imatinib resistance in CML patients: Value of pre-treatment genetic testing
and implication in patient-tailored therapy of Leukaemia. Annals of Oncology, May
2008, 19 (3): 40-41.
Page 13 of 32
42. Iqbal Z., Baig S.M., Aziz Z. and Akhtar T. Clinical significance of pre-existing
BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML)
patients: implication in prognosis and Imatinib follow-up studies. Annals of Oncology,
2007, 18(Supp. 4): iv4.
43. Iqbal Z. High frequency of pre-existing BCR-ABL gene ATP-binding domain
mutations associated with natural Gleevec resistance in chronic myeloid leukemia
(CML) patients. Haematologica, 2006; 91(s3): 3.
44. Iqbal Z. Frequency of chromosomal abnormalities and corresponding fusion
oncogenes in acute lymphoblastic leukemia (ALL) patients of Pakistan and its
implication in differential diagnosis and prognosis of leukemia. Haematologica, 2006;
91(s3):65.
45. Iqbal Z. Co-existence of fusion transcripts SIL-TAL1 and BCR-ABL in a
paediatric acute lymphoblastic leukaemia (ALL) patient. Haematologica, 2006;
91(s3):6.
46. Iqbal Z and Tanveer A. Detection of double fusion transcripts/ oncogenes (BCR-
ABL, SIL-TAL1) in childhood acute lymphoblastic leukaemia (ALL). Haematologica,
2006; 91(s3):68.
47. Iqbal Z and Tanveer A. A comprehensive analysis of pre-existing BCR-ABL
gene ATP-binding domain mutations associated with natural Gleevec resistance in
chronic myeloid leukemia (CML) patients. Haematologica, 2006; 91(s3):93.
Page 14 of 32
48. Iqbal Z and Tanveer A. First report of co-existence of double fusion transcripts
(BCR-ABL and E2A-PBX1) in t-cell acute lymphoblastic leukaemia (ALL).
Haematologica, 2006; 91(s3):68.
49. Iqbal Z. Eradication of Imatinib-resistance-conferring, pre-existing BCR-ABL
ATP-binding domain mutant clones by sustained interferon therapy in CML patients.
Haematologica, 2006; 91(s3):97
50. Iqbal Z and Tanveer A. Incidence of different fusion oncogenes in acute
lymphoblastic leukemia (ALL) patients from Pakistan: possible implication in
differential diagnosis, prognosis, treatment and management of ALL. Haematologica,
2006; 91(s3):64.
51. Iqbal Z. Detection of ring chromosome 21 and Philadelphia chromosome (t
9:22) in a chronic phase CML patient and its response to interferon and Imatinib
treatments. Haematologica, 2006; 91(s3):99.
52. Iqbal Z and Baig SM. Optimization of simple PCR assay for detection of Globin
gene deletions in alpha-thalassemia patients. Haematologica, 2006; 91(s3): 136.
53. Iqbal Z. Detection of BCR-ABL ATP-binding domain mutations in Imatinib
resistance CML patient who relapsed after bone marrow transplant. Haematologica,
2006; 91(s3): 139.
54. Iqbal Z, Aziz Z and Tanveer A. Clinical and molecular biological studies on
susceptibility and resistance to Imatinib in Pakistani CML patients: first
comprehensive report from South-East Asia. Haematologica, 2006; 91(s3):98.
Page 15 of 32
Iqbal Z and Tanveer A. High incidence of BCR-ABL fusion oncogene in Pakistani
childhood acute lymphoid leukaemia (ALL) patients reflects ethnic differences in
molecular genetics of ALL. Haematologica, 2006; 91(s3):65.
55. Iqbal Z, Abid Sohail Taj and Tanveer a. Studies on post bone marrow transplant
(post-BMT) Imatinib resistance in a chronic myeloid leukaemia (CML) patient.
Haematologica, 2006; 91(s3): 139.
56. Iqbal Z, Aziz Z, Shah IH and Tanveer A. Interferon therapy prior to Imatinib
can eradicate pre-existing BCR-ABL ATP-binding domain mutations conferring
natural Imatinib resistance in CML patients. Haematologica, 2006; 91(s3):96
57. Iqbal Z, Aziz Z, Shah IH, Khalid M and Tanveer A. First report of ring
chromosome 21 and Philadelphia chromosome (BCR-ABL fusion gene) in a 40 years
old CML patient resistant to Hydroxyurea: response to interferon and Imatinib.
Haematologica, 2006; 91(s3):97.
58. Iqbal Z. Case report of co-existence of double fusion transcripts (BCR-ABL,
E2A-PBX1) in T-cell acute lymphoblastic leukaemia (ALL). Haematologica, 2006;
91(s3):64.
59. Siddiqui R. T., Qureshi J. A. and Iqbal Z. Development of quantitative
competitive reverse transcriptase PCR (QC-RT-PCR) for detection of minimal
residual disease (MRD) and monitoring anti-leukaemic therapy response in
philadelphia chromosome positive leukemia. Haematologica 2004, 89 (suppl.n.6):94.
60. Iqbal Z., Aziz Z., Siddiqui R.T., Qureshi J. A. and Khalid A.M. first report of
multiple point mutations in BCR-ABL gene ATP-binding domain conferring primary
Page 16 of 32
Imatinib resistance in chronic myeloid leukemia patient. Haematologica 2004, 89
(suppl.n.6):97.
Articles presented at prestigious international Conferences (published
as proceedings):
61. Zafar Iqbal; Akhtar Tanveer; Shahid Mahmood Baig; Zeba Aziz; Mudassar
Iqbal; et al. T315I and M351T are the most frequent prior-to-Imatinib BCR-ABL
kinase domain mutations in chronic phase CML patients and lead to natural Imatinib
resistance. In: Online Proceedings of Second AACR (American Association for
Cancer Research)-Dead Sea International Conference on Advances in Cancer
Research: From the Laboratory to the Clinic, March 7-10, 2010, King Hussein Bin
Talal Convention Center, Dead Sea, Jordan.
62. Zafar Iqbal, Akhtar Tanveer, Mudassar Iqbal, Muhammad Ferhan, Shahid M.
Baig, Mubashar Iqbal Naqvi, et al. First comprehensive report of strong interplay of
genetic and environmental factors as well as high degree of ethnic and geographical
variations in biology of Leukemia as manifested by frequencies of common fusion
oncogenes of prognostic significance associated with different Leukemic subtypes in
Pakistani population. In: Online Proceedings of AACR (American Association for
Cancer Research) 100TH Annual Meeting—April 18-22, 2009; Colorado, Denver.
63. Zafar Iqbal, Zhao LiJuan, Shahid Baig, Zeba Aziz, Mudassar Iqbal, Ahmad
Khalid, and Tanveer Akhtar. Significance of pretherapeutic genetic testing in patient-Page 17 of 32
tailored therapy of leukemia as manifested by correlation of pre-Imatinib BCR-ABL
ATP-binding domain mutations and natural Imatinib resistance in CML patients . In:
Online proceedings of AACR (American Association for Cancer Research)
Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008;
Monterey, CA.
64. Iqbal Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer A
Interferon prior to Imatinib therapy eradicates pre-existing BCR-ABL ATP-binding
domain mutations conferring natural Imatinib resistance and leads to more
sustained/durable molecular response in chronic myeloid leukaemia. In: Proceedings
of, 6th Internal Symposium on Targeted Anti-cancer Therapies (TAT) 2008,
Bethesda USA, p. 39.
65. Iqbal Z., Baig S.M., Aziz Z., Akhtar T. Clinical significance of pre-existing
BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML)
patients: implication in prognosis and Imatinib follow-up studies. In: Proceedings of
5th International Symposium on Targeted Anticancer Therapies (TAT Congress),
Amsterdam, March 8-10, 2007, p.59.
66. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Tanveer A and Zeba Aziz. Unraveling
pharmacogenomic basis of primary Imatinib resistance: first report of multiple point
mutations in BCR-ABL gene ATP-binding domain conferring primary Imatinib
resistance in a ph chromosome positive chronic myeloid leukemia (CML) patient. In:
Proceedings of International Conference on Tumor Progression and Therapeutic
resistance, Philadelphia USA, November 8-9, 2004, pp: 56-5.
Page 18 of 32
A. Articles submitted to ISI- indexed journals / Prestigious Conferences:
67. Tashfin A, Iqbal Z., Sabir N, et al. Immunophenotypic characterization of
Pakistani pediatric Acute Lymphoid Leukemia Patients with respect to molecular
subtypes, clinical parameters and treatment outcome. Asian Pac J Cancer Prev.
68. Sabir N, Iqbal Z., Tashfin A, et al. Studies on Immunophenotypic characteristics
of Pakistani adult Acute Lymphoid Leukemia Patients: Association with molecular
subtypes, clinical parameters and treatment outcome. Asian Pac J Cancer Prev.
69. Mahmood Rasool, Zafar Iqbal, Mohammed Hussain Alqahtani, Ishfaq Ahmed
Sheikh et al. Comparative study of alterations in Tri-iodothyronine (T3), Thyroxine
(T4) hormone levels in breast and ovarian cancer in local population. Intl J Oncol.
70. Mahmood Rasool, Zafar Iqbal, Ishfaq Ahmed Sheikh et al. Evaluation of
biochemical markers and malondialdehyde status in patients with thyroid gland
dysfunction receiving interferon therapy. Oncol Reports.
B. GENEBANK (Nucleotide / NCBI) submissions / Citations :
DNA sequences of Hepatitis B Virus (HBV) surface antigen gene (HBsAg) were submitted to
GeneBank (NCBI Core Nucleotide) in 2001-2002. This was a part of M.Phil. research. GeneBank
database sequences’ IDs are:
AY168835-45 (11 sequences)
AF388661-8 (08 sequences)
Page 19 of 32
Molecular/Genetic Techniques Hands-on Training:
DNA/RNA/Protein extraction using Robotic arms (MagNApure, Roche), Kits and
Manual methods (TriZol and Phenol-Chloroform Extraction methods).
Real Time Q-PCR: Application in Gene Expression Profiling, Anti-cancer therapy
selection & follow-up, Genetic studies (Mutation detection, SNPs etc.).
M.R.D. (minimal residual disease) monitoring in Leukemia using RTQ-PCR.
Multiplex RT-PCR & ARMS-PCR (mutation/SNP detection) for Cancer genetic testing.
DNA sequencing using ABI310 and ABI 3500 Genetic Analyzers.
Cancer F.I.S.H. (Fluorescent in situ Hybridization) using CytoVision 7.2 system.
Cancer Microarray (cytoband) analysis using Affymetrix microarray system.
Sequenom (DNA Mass Spectrometry) for Cancer Gene mutations and SNP typing.
Intensive use of bioinformatics, biostatistics and Databases for DNA/RNA/Protein
analysis e.g. designing primers/probes, DNA sequencing, experimental design etc.
Recombinant DNA Techniques: Cloning, transformation, Restriction Analysis, etc.
Confocal Microscopy, Fluorescent Microscopy and bright- field microscopy.
Flow Cytometry, Fluorescent assisted cell sorting and Immunocytochemistry.
Western blotting.
Cell culturing (Human, Mice, bacteria); viral culturing; Chromosomal analysis etc.
Lentiviral/Liposomal gene transfer to mouse and Human tissues; mice experiments.
Eleven year experience of molecular diagnostics (MDx) as well as writing, planning,
execution, reporting, publishing and laboratory management of research / diagnostic /
clinical investigation projects in R&D sector and Hospitals as well as teaching/co-
supervising BS/MS/Phil students as well as PhD and post-PhD fellows at University level.
Page 20 of 32
Research Funding:
1. “Highthroughput cytogenetic and molecular analysis to reveal novel abnormalities
associated with transformation to advanced disease and tyrosine kinase inhibitor
resistance in Chronic Myeloid Leukemia” , by King Abdulaziz City for Science and
Technology (Project # ARP-35-200, funded amount Saudi Riyal 2 million equivalent
to Pk Rs. 54 million, 2015-2017), at National Guard Health Affairs, Riyadh, Saudi
Arabia (Principal Investigator).
2. “BCR-ABL mutations associated with resistance to imatinib in Chronic Myeloid
Leukemia patients”, by Higher Education Commission Pakistan (Project #
20-1370/R&D/09, funding amount PKRs 4.2 million, 2011-13), at Punjab University
Lahore Pakistan (Co-Investigator).
3. “Molecular genetic studies of Leukemia: Implication in differential diagnosis,
prognosis and anti-leukemia therapy monitoring”, by Shaukat Khanum Memorial
Cancer Hospital & Research Centre (SKMCH&RC) Lahore Pakistan (Funded amount
PKRs 3.0 million, 2009), at SKMCH&RC, Lahore, Pakistan (Principal Investigator).
4. Post-doctoral Fellowship Project “Functional characterization of NUP98-IQCG
fusion oncogene in acute leukemia”, funded by Shanghai Education Commission
Shanghai China (2007-2008), at Shanghai Institute of Hematology, Shanghai Jiao-
Tong University School of Medicine, Shanghai, China (Postdoctoral Scientist).
Page 21 of 32
5. “Y-chromosome microdeletions associated with male infertility in Pakistan”, funded
by Pakistan Science Foundation (Funded amount 1.0 million, 2004-6), at National
Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
(Co-Investigator).
6. Project “Low density lipoprotein receptor gene (LDLR) mutations associated with
familial hypercholesterolemia”, funded by Pakistan Science Foundation (Funded
amount 1.0 million, 2006-8), at NIBGE, Faisalabad, Pakistan (Co-investigator).
Research Awards:
1. Wallace H. Coulter Foundation-ASH (American Society of Hematology)
Abstract Achievement Award, ASH Annual Meeting, Dec. 2014, San Francisco, CA, USA.
2. ASH Abstract Achievement Award, ASH Annual Meeting, Dec. 2013, New Orleans,
LA.
3. European Hematology Association Travel Grant 2013: Annual Meeting, Sweden.
4. ASH (American Society of Hematology) Travel Award, ASH Annual Meeting, Dec.
2010.
5. Susan G. Komen / AACR Scholar-in-Training Award 2010: American Association
for Cancer Research (AACR) Award, AACR Special Conference “Advances in Cancer
Research-From Laboratory to Clinic” at Amman, Jordan, from March 07-10, 2010.
6. AACR / ITO EN Scholar-in-Training Award 2009: AACR 100TH Annual Meeting—April
18-22, 2009; Colorado, Denver.
Page 22 of 32
7. Shanghai Education Commission Fellowship (Clinical Hematology):
Research/clinical training at Shanghai Jiao-Tong University College of Medicine China in the
field of Functional Medical Genomics / Clinical Hematology.
8. SIES Award 2006: Italian Society of Experimental Hematology (SIES) in IX Congress
of this society (September 2006); research paper “Role of Pre-existing BCR-ABL gene ATP-
binding domain mutations in outcome of Gleevec therapy in CML”.
9. PSF Travel Award: Pakistan Science Foundation (PSF) Travel award to participate in
VIII Congress of Italian Society of Experimental Hematology (September 2006).
10. Best Cancer Researcher Award: Awarded by Society of Clinical Oncology Pakistani
(SCOP) on occasion of their 10th National and 1st International cancer conference (18th-21st
December 2003), for best cancer research article in the field of Leukemia.
11. Educational Scholarships : Educational Merit Scholarships by University &
Educational Boards in Ph.D., M.Phil., Grade-12, Grade-10 and Grade-5 classes (1985-2002).
University / Medical College Teaching and Academic Experience:
1. Curriculum design and teaching a course on “Molecular Pathology Course for Pathology
Residents / Fellows / Consultants ” at Department of Pathology, Kind Abdulaziz Medical
City, National Guard Health Affairs, Riyadh, Saudi Arabia (Since 2013).
2. Curriculum design and Teaching subjects of “Medical Genetics, Molecular Diagnostics
and Immunology” at College of Applied Medical Sciences and College of Medicine, KSA-
UHS, National Guard Health Affairs, Riyadh, Saudi Arabia (Since November 2012).
3. Taught the subjects of “Molecular Genetics and Hematology/Oncology” to “Medical
Residents and Fellows of KSU-Fellowship Program in Hematology / Pathology” at
Page 23 of 32
Department of Pathology, King Saud University College of Medicine, King Khalid
University Hospital, Riyadh (Since 07-06-2010).
4. Developed the CURRICULA for MS/PhD program in Molecular Genetic Pathology at King
Saud University College of Medicine, Riyadh, Saudi Arabia.
5. Developed the 5-year program for research, teaching and clinical services at Molecular
Genetic Pathology Unit, King Saud University College of Medicine, King Khalid University
Hospital, Riyadh, Saudi Arabia.
6. Taught the subjects of “Advanced Molecular Biology, Cancer Biology, Molecular
Hematology, Leukemia Genetics, Molecular Pathology and Advanced Experimental
Biology” to “BS, MS and PhD students” , as Assistant Professor at Centre for Research in
Molecular Medicine (CRiMM), Institute of Molecular Biology and Biotechnology (IMBB),
The University of Lahore, Lahore, Pakistan.
7. Developed the curricula for above-mentioned subjects (12-2009 to 06-2010).
8. A: Taught the subjects of “Advanced Molecular Biology, Human Cytogenetics,
Leukemia Genetics, Cancer Biology, Molecular Hematology and Molecular Pathology”
to “MS and PhD students” as Visiting Scientist at Faculty of Biological Sciences, Dep’t of
Zoology, University of the Punjab, Lahore, Pakistan. B: Developed the
curricula for the mentioned subjects (1-2009 to 06-2010).
9. Taught the subjects of “Human Molecular Genetics, Molecular Hematology and Cancer
Genetics” to “MS /PhD students” as Scientific Officer at Human Molecular Genetics
Group , Health Biotechnology Division, National Institute for Biotechnology & Genetic
Engineering (NIBGE), Faisalabad, Pakistan from (5/2002 to 1/2006).
Page 24 of 32
10. Taught the subjects of “Molecular Parasitology and Vector Biology” to “BS and MS
students” as Research Officer at Faculty of Biological Sciences, Dep’t of Zoology,
University of the Punjab, Lahore, Pakistan (3-2001 to 05-2002).
MS/MPhil and PhD Research Co-supervision:
Completed / Thesis defense:
PhD supervised at University of the Punjab Lahore, 2013/2014.
1. PCR-based analysis of prognostically important fusion oncogenes in Pakistani
pediatric acute lymphoblastic leukemia patients and their association with disease
biology and treatment outcome (Tashfeen Awan, Hematology/ Genetics) 2013.
2. PCR-based analysis of prognostically important fusion oncogenes in Pakistani
pediatric acute lymphoblastic leukemia patients and their association with disease
biology and treatment outcome (Noreen Sabir, Hematology/ Genetics) 2014.
3. BCR-ABL mutations associated with Imatinib resistance and advanced disease phases
in Chronic Myeloid Leukemia (Afia M. Akram, Hematology /Genetics) 2014.
4. Molecular Genetic studies of Acute Myeloid Leukemia in Pakistan (Sana Shahbaz,
Hematology/Genetics) 2015; Thesis submitted 2015.
MS/MPhil (University of The Punjab, Lahore) (Cancer Pharmaco-genomics) 4
MPhil (University of Health Sciences, Lahore) (Cancer Genetics) 1
MPhil (NIBGE Faisalabad) MS/MPhil (Human Molecular Genetics) 2
In Process (University of the Punjab Lahore Pakistan):
One Post-doctoral Fellow (Molecular Basis of Drug Resistance in Leukemia).
Page 25 of 32
7 PhDs (Molecular Genetics of Hematological Neoplasms and Breast Cancer).
One MS/MPhil (Genetics of Nilotinib resistance in Ph+ Leukemia).
Personal Details:
Date of Birth: Nov. 08, 1977 Passport #: AH1331772
Nationality: Pakistani (33100-4932177-9)
Congress and Symposia Attended:
1. American Society of Hematology (ASH) Annual Meeting, Dec. 2014, San Francisco, CA.
2. European Hematology Association (EHA), Annual Meeting June 2014 Milan Italy.
3. ASH-Highlights Asia Meeting, 29-30th Mar 2014, Singapore.
4. ASH Annual Meeting, Dec. 2013, New Orleans, LA.
5. Second Saudi CML Summit 2011. Hilton Hotel Jeddah, Saudi Arabia (Jan 27, 2011).
6. Saudi Hematology Association Conference, Riyadh Saudi Arabia (Sep 29, 2010).
7. American Association for Cancer Research (AACR) Special Conference “Advances in
Cancer Research-From Laboratory to Clinic” at Amman, Jordan, (March 07-10, 2010).
8. 12th National Haematology Conference, Lahore, Pakistan (Feb 9-16, 2010).
9. AACR 100th Annual Meeting, Denver, .Colorado. (April 18-22, 2009)
10. 21st Century Challenges in Hematology” (20th Anniversary of Shanghai Institute of
Hematology, Rui-Jin Hospital), Jiao-Tong University School of Medicine, China (Oct 2008).
11. 5th International Symposium on Targeted Anticancer Therapies (TAT Congress),
Amsterdam, Netherlands (March 8-10, 2007).
12. IX Congress, Italian Society of Experimental Hematology, Milano, Italy (September 2006).
13. International Conference on Tumor Progression and Therapeutic resistance, Philadelphia
USA (November 8-9, 2004).
Page 26 of 32
14. 10th National/1st International cancer conference, Pakistani Society of Clinical Oncology,
Pearl continental Hotel, Peshawar, Pakistan (18th-21st December 2003).
15. Symposium on "Molecular Biology Approach to Diagnostics & Prevention of Genetic
Diseases, CEMB, Punjab University, Lahore, Pakistan (Feb.4, 2000).
16. 17th Pakistan Congress of Zoology University of the Sind, Karachi, Pakistan (4/1997).
17. 18th Pakistan Congress of Zoology University of the Punjab, Lahore, Pakistan (4/1998).
Research-Degree Thesis / Reports Writing :
Postdoc (Post-PhD) Research (2007-8): “Functional Cell Molecular Biological
Studies of Leukemia” at Rui-Jin Hospital. Shanghai Institute of Hematology, Shanghai
Jiao-Tong University College of Medicine, Shanghai China. This work about
characterization of mutations and Leukemia stem cells in patients, cell lines and
mouse models, to see the effect of anti-leukemic therapy of Leukemic stem cells and
pre-clinical drug testing in vivo and in vitro.
PhD Thesis (2001-2007): “Molecular Genetic Studies of Leukemia in Pakistan”,
University of the Punjab, Lahore, Pakistan. This work was about the common fusion
oncogenes involved in Leukemogenesis and BCR-ABL mutations associated with
targeted anti-leukemic therapies in Philadelphia chromosome positive Leukemia.
M.Phil. (MS) Thesis (1991-2001): Phylogenetic Studies of Hepatitis B Virus (HBV)
Isolates of Pakistan: Pre-S Region DNA Variation, Genotyping and its Clinical
Page 27 of 32
Implications, University of the Punjab, Lahore, Pakistan. June 2001. This was first-time
Genotyping of HBV clinical isolates in Pakistan.
M.Sc. Thesis (1996-8): Some Studies on Pathogenic Bacteria Isolated from Freshwater
Physid Snails and Their Role as Snail Controlling Agents. University of the Punjab,
Lahore, Pakistan. This work was related to bacterial and parasitological studies of
Fascioliasis vectors, and their bacterial histo-pathological studies.
Taught Courses Studied:
Post-doctorate (Post-PhD): Hematology, Oncology, Immunology, Functional
Medical Genomics, Advanced research techniques.
PhD (Doctorate): Human Medical Genetics, Molecular Hematology, Cancer Biology,
Advanced Molecular Biology /Genetics, Cytogenetic, Pharmacogenetic, Cell Biology,
Molecular Physiology & Infectious Biology.
M. Phil. (MS): Basic & advanced Molecular Biology, Gene regulation & expression,
Medical Genetics, Recombinant DNA techniques, Molecular Immunology, Virology,
Molecular Toxicology, Bio-computation (PCGENE, DNA STAR, GENERUNNER) and
Bio-statistics.
M.Sc. (Masters) : Cell biology, Molecular Biology, Human Physiology, Animal
Physiology, Neurology, Cancer Biology, Biochemistry, Developmental Biology, Genetics,
Embryology, Physiological Anatomy, Microbiology, Parasitology, Environmental
Page 28 of 32
Biology, Wildlife, Conservation Biology, Palaeontology, Evolution, Taxonomy,
Zoogeography, Biostatistics.
B.Sc. (Bachelor): Human and Comparative Vertebrate Anatomy, Cell Biology, Genetics,
Biochemistry, Medical Mycology, Organic Chemistry, Inorganic Chemistry, Physical
Chemistry, Phycology and English
F.Sc. (Grade-12): Physics, Biology, Chemistry and English.
S.S.C. (Grade-10): Mathematics, Physics, Biology, Chemistry and English.
Membership of International Research Bodies/Agencies:
I. American Association for Cancer Research (AACR)
II. European Hematology Association (EHA)
III. American Society of Clinical Oncology (ASCO)
IV. American Society for Pediatric Hematology and Oncology (ASPHO)
V. Saudi Society for Bone Marrow Transplantation (SSBMT)
VI. National Academy of Young Scientists (NAYU), Pakistan.
VII. Fellow, Shanghai Institute of Hematology (SIH), China.
VIII. Society of Clinical Oncology Pakistan (SCOP).
IX. President, Pakistan Society for Molecular and Clinical Hematology (A partner of
American Society of Hematology).
Page 29 of 32
References:
1) Dr Rizwan C. Naeem, MD, PhD, FACMG, DABMG
Professor of Pathology & Director Molecular Pathology
Director ABMG Lab Genetics Fellowship Program
Albert Einstein College of Medicine and Montefiore Medical Centre
Bronx, NY, USA.
Phone: 718-405-8101; Fax: 718-931-3637
Email: [email protected]
2) Professor Dr Masood A. Shammas, PhD
Director, Translational Genomic Instability Program
Jeromy Lipper Myeloma Center
Page 30 of 32
Harvard (Dana Farber) Cancer Institute
Research Health Scientist, VA Boston Health Care System
Harvard Medical School at VAMC
Harvard University
West Roxbury, MA 02132
Phone: 1-857-203-6172 Office
Fax: 1-781-507-1075 Cell
E-mail: [email protected]
3) Dr Muhammad Faiyaz-Ul-Haque, MPhil PhD FRCPath
Professor and Consultant
Director, Molecular Pathology Unit
Department of Pathology and Laboratory Medicine
College of Medicine and King Khalid University Hospital
King Saud University, Riyadh 11461, Pakistan.
Phone: +966-1-469-9377
E-mail: [email protected] , [email protected]
4) Dr Muhammad Azhar Chishti, DVM PhD
Scientist, University of Toronto
4424 Marshdale Court, Mississauga ONT L5M 4G1, Canada.
Phone: +1-905-593-8835
E-mail: [email protected]
5) Professor Tanveer Akhtar, PhD Post-doctorate (Manitoba)
Dean, Faculty of Biological Sciences
Page 31 of 32
Director, Higher Education Project in Hematology, Oncology and
Pharmacogenetic Engineering Sciences (HOPES), Health Sciences Laboratories,
Faculty of Biological Sciences, Department of Zoology, University of the Punjab,
Lahore 54590, Pakistan.
Visiting Scientist, Montefiore Medical Centre,
111 East 210th Street, Bronx, NY 10467, USA.
Phone: +92-321-4257861, +92-42-9923124
E-mail: [email protected]
Page 32 of 32
![Blackholer Baccha (Kid of Blackhole) a Science Fiction by Muhammad Zafar Iqbal [Amarboi.com] (3)](https://img.dokumen.tips/doc/110x75/55cf9d96550346d033ae470e/blackholer-baccha-kid-of-blackhole-a-science-fiction-by-muhammad-zafar-iqbal.jpg)
